An Israeli blood diagnostic technology startup showcased by TrialSite News called Sight Diagnostics secured a deal with Sheba Medical Center in Israel to mitigate the risk of contamination by COVID-19. The Israeli provider will utilize the startup’s technology—OLO blood analyzer—to provide rapid full blood count (FBC) results in a dedicated lab within this flagship, government-run hospital. The aim: process samples of infected patients who are being monitored and treated in a separate field hospital.
The Parties Conducted a Two-Month Successful Pilot
This announcement was preceded by a pilot where Sheba Tel Hashomer ran a two-month evaluation at the central lab of Sheba Tel Hashomer, one of the top 10 hospitals in the world. The pilot results led to the implementation of OLO for ongoing FBC testing at the hospital.
The Diagnostic Product: OLO
Now, OLO is used for routine testing of Sheba’s positive coronavirus patients. OLO technology combines computer vision and artificial intelligence (AI) to digitize each blood sample into more than 1,000 high resolution images.
Prior to the adoption of the OLO diagnostic technology, a health worker would ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).